Whether vaccine effectiveness against Coronavirus disease 2019 (Covid-19) lasts longer than 6 months is unclear.
A retrospective cohort study was conducted using Swedish nationwide registries. The cohort comprised 842,974 pairs ( N=1,684,958 ), including individuals vaccinated with 2 doses of ChAdOx1 nCoV-19 [ Oxford / AstraZeneca; Vaxzevria ], mRNA-1273 [ Moderna; Spikevax ] , or BNT162b2 [ Pfizer / BioNTech: Comirnaty ], and matched unvaccinated individuals.
Cases of symptomatic infection and severe Covid-19 ( hospitalization or 30-day mortality after confirmed infection ) were collected from 12 January to 4 October 2021.
Vaccine effectiveness of BNT162b2 against infection waned progressively from 92% ( 95% CI, 92-93, P less than 0·001 ) at day 15-30 to 47% ( 95% CI, 39-55, P less than 0·001 ) at day 121-180, and from day 211 and onwards no effectiveness could be detected ( 23%; 95% CI, -2-41, P=0·07 ).
The effectiveness waned slightly slower for mRNA-1273, being estimated to 59% ( 95% CI, 18-79 ) from day 181 and onwards.
In contrast, effectiveness of ChAdOx1 nCoV-19 was generally lower and waned faster, with no effectiveness detected from day 121 and onwards ( -19%, 95% CI, -97-28 ), whereas effectiveness from heterologous ChAdOx1 nCoV-19 / mRNA was maintained from 121 days and onwards ( 66%; 95% CI, 41-80 ).
Overall, vaccine effectiveness was lower and waned faster among men and older individuals. For the outcome severe Covid-19, effectiveness waned from 89% ( 95% CI, 82-93, P less than 0·001 ) at day 15-30 to 42% ( 95% CI, -35-75, P=0·21 ) from day 181 and onwards, with sensitivity analyses showing notable waning among men, older frail individuals, and individuals with comorbidities.
In conclusion, vaccine effectiveness against symptomatic Covid-19 infection wanes progressively over time across all subgroups, but at different rate according to type of vaccine, and faster for men and older frail individuals.
The effectiveness against severe illness seems to remain high through 9 months, although not for men, older frail individuals, and individuals with comorbidities.
This strengthens the evidence-based rationale for administration of a third booster dose. ( Xagena )
Source: University of Umea - Papers SSRN, 2021